Ikaros Transcription Factor
"Ikaros Transcription Factor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A transcription factor that plays a role as a key regulator of HEMATOPOIESIS. Aberrant Ikaros expression has been associated with LYMPHOBLASTIC LEUKEMIA.
| Descriptor ID |
D051740
|
| MeSH Number(s) |
D12.776.260.522.500 D12.776.930.375.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Ikaros Transcription Factor".
Below are MeSH descriptors whose meaning is more specific than "Ikaros Transcription Factor".
This graph shows the total number of publications written about "Ikaros Transcription Factor" by people in this website by year, and whether "Ikaros Transcription Factor" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2009 | 1 | 1 | 2 |
| 2010 | 0 | 2 | 2 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 0 | 2 | 2 |
| 2014 | 2 | 0 | 2 |
| 2015 | 1 | 2 | 3 |
| 2016 | 0 | 1 | 1 |
| 2017 | 2 | 1 | 3 |
| 2019 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 2 | 3 | 5 |
| 2022 | 0 | 1 | 1 |
| 2023 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Ikaros Transcription Factor" by people in Profiles.
-
Dominant negative variants in IKZF2 cause ICHAD syndrome, a new disorder characterised by immunodysregulation, craniofacial anomalies, hearing impairment, athelia and developmental delay. J Med Genet. 2023 11; 60(11):1092-1104.
-
Detection of recurrent colorectal cancer with high specificity using a reporting threshold for circulating tumor DNA methylated in BCAT1 and IKZF1. Cancer. 2022 05 15; 128(10):1921-1928.
-
Modeling IKZF1 lesions in B-ALL reveals distinct chemosensitivity patterns and potential therapeutic vulnerabilities. Blood Adv. 2021 10 12; 5(19):3876-3890.
-
Association of Combined Focal 22q11.22 Deletion and IKZF1 Alterations With Outcomes in Childhood Acute Lymphoblastic Leukemia. JAMA Oncol. 2021 Oct 01; 7(10):1521-1528.
-
A hotspot mutation in transcription factor IKZF3 drives B cell neoplasia via transcriptional dysregulation. Cancer Cell. 2021 03 08; 39(3):380-393.e8.
-
Targeting oncoproteins with a positive selection assay for protein degraders. Sci Adv. 2021 02; 7(6).
-
Enhancer polymorphisms at the IKZF1 susceptibility locus for acute lymphoblastic leukemia impact B-cell proliferation and differentiation in both Down syndrome and non-Down syndrome genetic backgrounds. PLoS One. 2021; 16(1):e0244863.
-
Evaluation of Circulating Tumor DNA for Methylated BCAT1 and IKZF1 to Detect Recurrence of Stage II/Stage III Colorectal Cancer (CRC). Cancer Epidemiol Biomarkers Prev. 2020 12; 29(12):2702-2709.
-
Inherited genetic susceptibility to acute lymphoblastic leukemia in Down syndrome. Blood. 2019 10 10; 134(15):1227-1237.
-
Antagonism of B cell enhancer networks by STAT5 drives leukemia and poor patient survival. Nat Immunol. 2017 06; 18(6):694-704.